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Abstract Implanted devices are mainly used to improve
impaired function or to replace missing anatomic structures.
They are made of synthetic material or devitalized
biological structures. In contrast to vital transplants, they
are not rejected by the body. However, the host reacts
against these foreign bodies, a process which can be
designated as biocompatibility. The interaction of the
device with adjacent granulocytes and complement not
only induces various degrees of inflammation but also
impairs local microbial clearance. Foreign surfaces are a
preferred target for bacterial adherence. While adhering
bacteria are highly resistant to the bactericidal activity of
phagocytes, they are also resistant to most antimicrobial
agents. Certain bacteria may reside within host cells, and
hence, evade host defense mechanisms by persisting
intracellularly around implants. Nanotechnology minimizes
clotting activation and bacterial adhesion by intravascular
devices. Furthermore, surface coating with appropriate
substances favorably influences biocompatibility as well
as susceptibility to infection. In the future, “Microsystems
Technology” deployed as intelligent device may decrease
the risk of implant failure due to infection.
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Introduction
Implants are increasingly used in many types of surgery, to
improve impaired function, replace missing anatomic
structure, or optimize appearance [1, 2]. Such devices are
made out of different types of material, mainly metals and
polymers, but also biological materials such as devitalized
bone and blood vessels. Implant material is also called
biomaterial [3–5]. Whereas vascularized tissues or foreign
vital cells are not accepted by the host without immuno-
suppression, synthetic material and devitalized biological
devices are rarely rejected. Nevertheless, the host reacts to
such implants to different degrees which can be designated
as biocompatibility [6, 7].
A feared complication of implant surgery is bacterial or
fungal infection. Staphylococci are the most common
microorganisms causing implant-associated infections. In
a large series on almost 600 prosthetic joint infections, 30%
were caused by coagulase-negative staphylococci, 23% by
Staphylococcus aureus, 9% by streptococci, and 6% by
Gram-negative bacilli. However, virtually, all bacteria and
fungi are able to cause implant-associated infection,
including anaerobes and mycobacteria [8]. The increased
risk for infection has been observed in orthopedic [9, 10],
cardiovascular [11, 12], plastic reconstructive [13], general
surgery [14], and neurosurgery [15, 16]. The first experi-
mental proof for the increased susceptibility of foreign
material to infection was provided by Elek and Conen [17]
who showed that in the vicinity of suture material, the
minimal abscess-producing dose was only 100 colony
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forming units (CFU) of S. aureus. This was >100,000-fold
lower than in the absence of foreign material, an observa-
tion which was confirmed in an animal model of foreign
body-associated infection [18, 19]. Whereas >107 CFU S.
aureus did not produce any abscesses in the absence of
foreign material, 100 CFU were sufficient to infect 95% of
the subcutaneous implants (tissue cages) in guinea pigs
(Fig. 1) [18]. In the same animal model, extravascular
devices could also be infected by the hematogenous route.
With an experimental bacteremia of 103 CFU S. aureus per
milliliter blood, seeding only to the device, and not to any
additional site, was detected in 42% [20]. This experimental
observation reflects the clinical data showing that S. aureus
sepsis in patients with orthopedic implants results in
prosthetic joint-associated infection in one third of the
patients [21–23].
During the last three decades, the pathogenic factors
responsible for the enhanced risk for implant-associated
infection have been elucidated by many different
approaches [24–29]. In brief, the increased susceptibility
of implant material to pyogenic infections is due to
impaired host defense at the implant site, and to the
transformation of microorganisms in device-adhering
biofilms. In this review, the main focus is on the three-
way interaction between foreign material, host immune
response, and the microorganisms adhering to implants.
Type of implants
The type of material is of minor clinical importance
regarding the susceptibility of a device to infection. By
testing bacterial adherence in vitro, it could be shown that
biofilm-forming Staphylococcus epidermidis adhered to a
higher degree on pure titanium than on stainless steel.
However, this in vitro difference could not be observed in
an in vivo model, where no differences in infection rates
were observed when titanium and stainless steel implants
were challenged with staphylococci [30]. Thus, the imme-
diate protein coating of the implant by the host is more
relevant for bacterial adherence than the type of material.
Medical devices can be used either transiently or
permanently. Permanent devices, also called implants,
can be classified according to their localization as
intravascular or extravascular devices [31, 32]. This
differentiation is useful since the interaction with the host
is significantly different for the two types of devices.
Whereas intravascular implants mainly interact with
coagulation factors and circulating blood cells, extravas-
cular implants interact with surrounding tissue, interstitial
fluid, and attracted phagocytes [33, 34].
Intravascular devices Vascular prostheses are used for
revascularization in the case of arterial occlusive disease
[12, 35]. In addition, patients with chronic renal failure
undergoing hemodialysis need arteriovenous shunts which
are typically made of synthetic material (Gore-tex® or
Dacron®) [36]. Nowadays, the most common vascular
implants are intravascular stents which are mainly used in
interventional cardiology, but also to restore the blood
flow in large vessels such as the aorta or the carotid artery
[37, 38].
Artificial heart valves are used for valvular stenosis or
regurgitation [11, 39]. Interestingly, not only synthetic but
also biological devices of devascularized tissue (e.g.,
porcine bioprosthesis) increase the susceptibility to infec-
tion. In a randomized prospective trial comparing mechan-
ical heart valves with porcine bioprostheses, the risk for
endocarditis was not statistically different, when measured
at 10 and at 20 years [40, 41]. This indicates that a vascular
biological material seems to behave like synthetic material
in terms of susceptibility to infection.
Extravascular devices These implants are localized in
different compartments of the host and have no direct
interaction with the circulating blood. Orthopedic devi-
ces, such as prosthetic joints and internal fixation devices
(nails, plates, and screws), are by far the most frequent
implants in human medicine [9, 10, 42–44]. Despite the
fact that joint replacement is a so-called clean procedure
[45], implant-associated infections are observed in 0.5%
Fig. 1 Guinea pig with subcutaneously implanted perforated cylinder
(tissue cage) made of Teflon. Interstitial fluid and cells are
accumulating in the tissue cages. Host defense mechanisms surrounding
the foreign body can be studied ex vivo by drawing tissue-cage
fluid [18, 24, 55]
296 Semin Immunopathol (2011) 33:295–306
(hip arthroplasty) to 7.5% (elbow or ankle arthroplasty) of
the cases [9, 46].
Host defense mechanisms
Innate or nonspecific host defense mechanisms are required
for rapid and efficacious elimination of microorganisms
causing implant-associated infection [18, 24, 25, 47]. As
mentioned above, implanted devices are susceptible to
virtually all types of bacteria and fungi [1, 48, 49].
Microorganisms are attacked by granulocytes or mononu-
clear phagocytes. Killing of bacteria by these cells depends
on efficient phagocytosis and intracellular killing. For rapid
ingestion of bacteria, opsonization of the microorganisms is
essential. This involves nonspecific (complement, bacterial
remnants) and in some microorganisms-specific soluble
components (antibodies), as well as the corresponding
receptors on the phagocytes. The process of phagocytosis
involves chemotaxis, cell adherence to the microorganism,
ingestion, killing, and digestion [50]. If this complex
process is impaired at a given level, there is an enhanced
risk of microbial persistence and therefore infection [51].
In view of the susceptibility of implants to infection,
various possible mechanisms for the impaired bacterial
clearance have been hypothesized. In addition, the paradox
of microbial persistence in the presence of abundant
granulocytes around the implant has been studied.
Interaction of implanted device with host defense
mechanisms
An implanted device interacts both with different host factors
and with microorganisms. As soon as synthetic material is
introduced in the body, it is covered by host proteins such as
fibronectin, fibrinogen, and laminin. These proteins rather
increase than decrease the risk for infection, because they act
as mediators for bacterial adherence [52–54]. In addition,
granulocytes and complement directly interact with the
implant which may contribute to inflammation.
Frustrated phagocytosis Infections around implants occur
after seeding of even very low numbers of bacteria to the
device. Despite the presence of macrophages and granulo-
cytes around the implant, these microorganisms cannot be
cleared (Fig. 2). Implant-associated infections never heal
spontaneously, be it in humans or in experimental models
using guinea pigs or mice with subcutaneous foreign bodies
[18, 55–57]. Such infections are characterized by their
protracted evolution. This is typically observed within the
periprosthetic tissue. Moreover, bacteria persist at the
implant site until spontaneous extrusion or surgical remov-
al. In view of these clinical and experimental character-
istics, it has been hypothesized that the interaction of
granulocytes with a nonphagocytosable surface (i.e., im-
plant), or alternatively with wear particles, may impair the
function of granulocytes [18, 24, 58]. To test this
hypothesis, a guinea pig model using subcutaneous tissue
cages as foreign devices has been developed (Fig. 1) [55].
Similar to the clinical observation, these implants (i.e.,
tissue cages) are highly susceptible to colonization by very
low numbers of staphylococci. This is also true for so-
called apathogenic bacteria such as S. epidermidis [19] or
Propionibacterium acnes (unpublished data). In the inside
of the tissue cages, interstitial fluid and phagocytes
accumulate in close contact to the foreign surface. Fluid
and phagocytes can be easily sampled by percutaneous
puncture. Hence, with this model, local host defense
mechanisms are accessible for ex vivo analysis (Fig. 1).
For example, it has been shown that granulocytes around
the subcutaneous implant are unable to efficiently kill
staphylococci, despite their adequate opsonization [18].
Also, opsonized particles are inefficiently ingested, and
the granulocytes are partially degranulated and have a
decreased production of oxygen radicals [24]. These
observations could be further elucidated with in vitro
experiments. When comparing the interaction of granulo-
cytes with and without exposure to Teflon fibers, the
respiratory burst and the extracellular release of specific
granules are increased in granulocytes exposed to fibers.
These granulocytes show a similar defect as tissue cage
granulocytes, notably, as cells which interact with a
Fig. 2 Scanning electron micrograph (SEM) of an experimental
implant-associated infection. Teflon tissue cages were implanted in the
subcutaneous tissue of guinea pigs. After complete healing, 106 CFU
S. aureus Wood 46 were directly inoculated into tissue cages.
Sampling for SEM was performed 3 h after infection. The picture
shows two granulocytes which are obviously not able to eliminate
staphylococci. S. aureus is visible as aggregates. The irregular surface
shows exopolysaccharides
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nonphagocytosable surface in vivo [24]. This process is
called frustrated phagocytosis [59, 60].
Biomaterial surface activates neutrophils, but also
induces a defect in subsequently added neutrophils [61].
These defects are likely due to the observed induction of
degranulation of antimicrobial peptides (defensins) by the
biomaterial, and hence impaired bactericidal activity [61].
This deactivation can be abrogated by specific antibodies to
defensins. Another mechanism also resulting in impaired
phagocytosis around implanted biomaterials has been
proposed by Chang et al. [62]. They exposed neutrophils
to different biomaterials used in vascular surgery. Their
main finding was an enhanced production of oxygen
radicals during neutrophil adherence to roughened but not
smooth polystyrene surfaces. The reactive oxygen-
intermediates induce a nonapoptotic cell death [62]. Taken
together, these interactions lead to neutrophil deactivation
and premature cell death resulting in impaired microbial
clearance around implants.
Since granulocytes around an implant are functionally
impaired, the risk of bacterial adherence to the device is
high. After adherence, many species of bacteria rapidly
form a biofilm on the surface. Therefore, in implant-
associated infection, granulocytes are mainly confronted
with biofilm but not with planktonic bacteria. For effica-
cious clearance of adherent bacteria, leukocytes must
penetrate the biofilm. Leid et al. [63] observed that
leukocytes are able to penetrate S. aureus biofilms only
under laminar-shear, but not static conditions. This finding
may explain another observation. In infected vascular
grafts, bacteria are almost always found on the outside
and not on the luminal surface [64]. The luminal surface of
vascular grafts is commonly smooth and eventually covered
by endothelial cells. Hence, the bacteria mainly persist on
the outer part of a vascular prosthesis, where laminar-shear
forces are lacking [64].
Interaction of implant with complement During contact of
blood with the surface of an implant, complement is
activated. This phenomenon has been observed in patients
undergoing hemofiltration [65], hemodialysis [66], nylon
fiber filtration leukapheresis [67], heart valve exchange
[68], and vascular graft implantation [69]. In addition,
complement activation also occurs on the surface of
extravascular devices. This can result in local inflammation
[70]. Polymer surfaces from subcutaneously implanted
tissue cages (Fig. 1) interact with interstitial fluid, but do
not activate complement excessively [18]. However, even
limited complement activation may have an impact on local
inflammation by attracting phagocytes. Tang et al. [71]
tested the importance of biomaterial surface properties in
mediating in vivo complement activation. They evaluated
different materials for their potency to activate complement
in vitro and thereby to attract inflammatory cells on foreign
material in a mouse model. For this purpose, they
implanted devices of various materials intraperitoneally.
They found a close relationship between surface-mediated
complement activation in vitro and accumulation of
phagocytes on polymer surfaces in vivo. These results
show that complement activation is relevant not only upon
blood–biomaterial interaction but also in extravascular
devices interacting with interstitial fluid. Complement
activation around implants or wear debris may therefore
be the trigger of so-called aseptic loosening of joint
prostheses [72]. DeHeer et al. [73] tested the ability of
polyethylene to activate the complement cascade. Polyeth-
ylene is a component of artificial joints which is liberated as
wear particles. It could be shown that polyethylene particles
activate the alternative pathway of complement. In line with
this in vitro observation, the authors could detect comple-
ment fragment Bb around polyethylene particles accumu-
lating in synovial tissue of three patients. Since activated
complement results in recruitment of inflammatory cells,
these in vitro and in vivo observations support the
hypothesis of implant loosening by wear particles.
In addition to the foreign body itself, the bacterial
biofilm covering the implant activates complement also. S.
epidermidis biofilms activate more complement than
planktonically grown bacteria, as measured by C3a forma-
tion. Nevertheless, IgG and C3b deposition is diminished in
biofilm-embedded bacteria, indicating their capability to
evade phagocytosis [57]. Consequently, S. epidermidis
persists within the biofilm on the implant, but does not
cause massive inflammation, partially because 3b deposi-
tion is diminished. These experimental data parallel the
clinical observation that bacteria embedded in a biofilm
cause persistent low-grade infection. On the other hand,
they explain loosening of the device because of local
inflammation due to complement activation with C3a
release, and hence, attraction of phagocytes around the
implant [74].
Degranulation—effect on the host Neutrophils interacting
with foreign body material or with bacterial biofilm may
harm the host. In orthopedic surgery, the most frequent
cause for implant exchange is a noninfectious (i.e., aseptic)
loosening of the device. There is an ongoing debate about
the mechanism of implant loosening in patients without
obvious signs of infection [75]. It has been hypothesized
that at least some of these patients may have cryptic
infection [76]. However, joint loosening can also occur
without infection, by release of proteases into the interphase
of implant and bone.
Incubation of host cells with Teflon fibers in a medium
containing 50% plasma increases the oxidative metabolism
of granulocytes but also releases specific granules. This in
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vitro stimulation and degranulation are relevant in vivo.
Granulocytes purified from interstitial fluid surrounding
subcutaneous tissue cages (Fig. 1) are partially degranu-
lated. Granulocytes, which interacted with an implant in
vivo (i.e., tissue cage neutrophils), contain up to two thirds
less myeloperoxidase, lysozyme, beta-glucuronidase, and
B12-binding protein as compared to peritoneal exudate
neutrophils [24]. Thus, azurophil (myeloperoxidase) as well
as specific granules (B12-binding protein) are liberated
upon interaction with the implanted polyfluoroethylene
device. Since specific granules also contain proteases such
as collagenase, one could speculate that the observed
degranulation would result in loosening of bone-implanted
devices. Indeed, in patients with peri-implantitis, matrix
metalloproteinase 8 was detected in the peri-implant
sulcular fluid [77]. This human neutrophil collagenase
may lead to implant loosening. Along this line, it has been
shown that hydroxyapatite particles (coating of artificial
joints) activate granulocytes to release proinflammatory
mediators, such as metalloproteinase [78]. Again, this local
inflammation, induced by the interaction of granulocytes
with biomaterial, may result in implant loosening due to the
activity of collagenases.
Interaction of wear particles with phagocytes After arthro-
plasty, wear particles are produced in variable amounts
depending on the biomechanical situation. In addition to the
implant itself, these foreign particles also challenge the
immune system. Bernard et al. [58, 79] described an
impaired bactericidal activity of neutrophils after interaction
with wear particles. They incubated host cells with ultra-
high molecular weight polyethylene particles which simu-
lated in vivo wear debris. The bactericidal activity of
neutrophils decreased in a time- and dose-dependent
manner. Not only granulocytes but also macrophages are
abundant in the peri-implant tissue where wear debris is
present [80]. Macrophages try to eliminate wear particles
and liberate cytokines upon phagocytosis. Cytokines, such
as interleukin (IL)-1α, IL-1β, tumor necrosis factor (TNF)-
α, macrophage colony-stimulating factor (M-CSF), trans-
forming growth factor (TGF)-α, and many others have been
detected in tissue surrounding orthopedic implants [81].
Some of these cytokines, such as M-CSF and TGF-α,
directly stimulate osteoclastogenesis, which favors implant
loosening by bone resorption.
Influence of neointimal healing
The crucial role of the neointimal healing on susceptibility
to infection was described in a dog model, already 35 years
ago [82]. In this study, the rate of prosthetic graft associated
infection induced by intravenous bacteremic challenge
with 107 CFU S. aureus dropped from 100% during the
first 2 weeks after surgery to 30% 1 year after graft
implantation. Interestingly, there was an excellent correla-
tion between pseudointimal integrity and protection
against hematogenous seeding. None out of 26 Dacron®
grafts covered with an intima was infected during
experimental bacteremia, whereas 95% (54/57) were
infected in the case of incomplete or completely missing
neointima [82]. This observation was later confirmed by
testing different materials at different time intervals after
surgery [83]. Dacron® grafts were superior to the poly-
tetrafluoroethylene (PTFE) grafts with regard to suscepti-
bility to bacteremic infection and to intimal lining. After
3 months, 70% (7/10) of the “Ultralight weight knitted
Dacron®” grafts, but none out of 10 “PTFE-Gore-tex®”
grafts, had complete neointimal lining on visual examina-
tion. Accordingly, only 10% of the Dacron®, but 70% of
the Gore-tex® grafts, were infected after intravenous
challenge with 108 CFU S. aureus. This underlines the
crucial role of neoendothelization of the vascular devices
against bacterial infection.
Not only vascular grafts but also septal defect-occlusion
devices interact with blood components (complement,
thrombocytes, granulocytes) and serve as an attractive site
for bacterial adhesion. Therefore, rapid coverage by newly
formed tissues is crucial. Foth et al. [84] analyzed 10
human septal defect-occlusion devices explanted from
5 days to 48 months after implantation due to mechanical
reasons. With the exception of the implant with the shortest
implantation time of 5 days, all specimens with an
implantation time ≥10 weeks had a pseudointima with a
structured arrangement of endothelial cells. In addition,
within several months, neotissue was formed within the
wire mesh of the implant. These experiments rationally
support the clinical practice of anticoagulant or antiplatelet
therapy for 6 months after implantation. Thus, it can be
speculated that not only the risk for thromboembolic events
but also the increased susceptibility to infection is markedly
decreased after complete tissue coverage of the foreign
device.
Phagocytosis of device-adherent bacteria
Microorganisms involved in device-associated infection
attach to the foreign surface and grow as a so-called
biofilm [85–88]. Their phenotype is different from those in
other types of infection where they exist in a planktonic
stage. The process of biofilm formation has been exten-
sively studies, especially with S. aureus and S. epidermidis.
The first step of staphylococcal biofilm formation is
adhesion to host proteins covering the artificial surface.
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Important adhesins of staphylococci are fibronectin-binding
protein A, collagen-binding protein, fibrinogen-binding
protein, and protein A. Primary adhesion is followed by
accumulation and by production of exopolysaccharides.
This thereby formed complex structure is called biofilm.
Within biofilms, microorganisms develop into organized
communities resembling multicellular organisms. Biofilm
bacteria behave differently regarding their capacity to resist
host defense mechanisms or antimicrobial agents. Adherent
bacteria are highly resistant to antibiotics even if their
planktonic forms are perfectly susceptible [19, 89–92]. It is
therefore conceivable that adherent bacteria are also more
resistant than planktonic bacteria to phagocytosis and
killing by host cells. Intact neutrophils show a significantly
compromised elimination of biofilm bacteria. In a study by
Vaudaux et al. [93], >95% of the S. aureus adhering to
polymethylmethacrylate survived exposure to purified
neutrophils, as compared to <10% of planktonic staphylo-
cocci under otherwise identical conditions. More recently,
Kristian et al. [57] compared the survival of clonally
identical biofilm and planktonic S. epidermidis. Biofilm
staphylococci were significantly more resistant to neutro-
phils than planktonic staphylococci (67% survival vs 21%
survival, p<0.03). This illustrates superbly that S. epider-
midis belongs to the most important microorganisms in
implant-associated infection, as observed in clinical prac-
tice. Despite its very low pathogenicity in the immuno-
competent host, it has a high pathogenicity in the vicinity of
an implanted device [94].
Intracellular persistence of bacteria
in implant-associated infections
Bacteria causing implant-associated infections may escape
the first lines of immune defense by residing intracellularly.
Host cells are either professional phagocytes (i.e., mono-
cytes or macrophages), or nonprofessional phagocytes, such
as endothelial or epithelial cells or fibroblasts. According to
their association with host cells, bacteria can be classified
into (1) obligate intracellular, (2) facultative intracellular
bacteria, and (3) microorganisms that are traditionally
considered extracellular pathogens but have the capacity
to reside intracellularly. Obligate intracellular bacteria, such
as Rickettsia spp., Chlamydia spp., or Coxiella burnetii, are
unable to grow outside of host eukaryotic cells. Facultative
intracellular bacteria, such as Mycobacteria spp., Listeria
spp., Shigella spp., and Salmonella spp., are free-living
organisms that naturally invade host cells. Finally, “small
colony variants” of bacteria that are traditionally considered
extracellular, such as Staphylococcus spp., Pseudomonas
spp., or Escherichia coli, constitute a subpopulation of the
identical microorganism but with distinctive phenotypic
and pathogenic features allowing persistence within host
cells [49, 95].
Obligate intracellular bacteria Among the various bacteri-
al genera belonging to this group, predominantly C.
burnetii—the organism responsible for Q-fever—has been
described in implant-associated infections, in particular in
prosthetic heart valve [96] and vascular graft infections [97,
98]. The pathogenesis and clinical features of Q-fever have
been described elsewhere [99], and are beyond the scope of
this review. However, after C. burnetii is phagocytosed by
macrophages and monocytes, the DNA of Coxiella sp. can
still be found in circulating monocytes and in the bone
marrow, many years after primary infection [100]. Hence,
the pathogen has specific strategies to survive in host cells,
but escapes intracellular killing [100–102]. Because of this
persistence, it is possible that host cells initiate the implant-
associated infection. This hypothesis can be supported by
two observations, illustrating an overlap between the host
response to implant-associated infections and that to C.
burnetii. Firstly, the pathogen causes a predominant
lymphocyte infiltration at the site of infection. In 50% of
vascular graft implants, irrespective whether or not an
infection is present, a significant lymphocytic population is
found [64]. Secondly, significant amounts of the cytokine
IL-10 are observed in close proximity to implants [103]. On
the other hand, high levels of IL-10 are associated with
persistence of C. burnetii [104]. Therefore, circulating host
cells containing C. burnetii may be involved at the implant
site where they act as “Trojan horses.”
Facultative intracellular bacteria Salmonella spp. and
Listeria spp. as well as Mycobacterium tuberculosis and
nontuberculosis Mycobacteria have been reported in asso-
ciation with both intravascular and extravascular foreign
body infections [105–112]. However, the host response to
these bacteria is different. Salmonella spp. and Listeria spp.
cause acute inflammation at the site of infection. In
contrast, the immune response to Mycobacterium spp. is
typically chronic.
Primary infection with M. tuberculosis occurs in the
lung. This is followed by mycobacteremia in which small
numbers of microorganisms disseminate to the implant by a
mechanism that involves migration of mycobacteria within
dendritic cells [111, 113]. Though, adherence and biofilm
formation of M. tuberculosis on implant surface are not
strong. Ha et al. [30] compared these properties of S.
epidermidis with those of M. tuberculosis on four different
types of metal segments. M. tuberculosis rarely adhered to
metal surfaces and showed very little biofilm formation.
Similar results were reported by Chen et al. [114] who
compared S. aureus and M. tuberculosis in vitro and in
vivo. These data suggest that the immune response to
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mycobacterial implant-associated infection is not significantly
different from that to other extrapulmonary infections.
Salmonella spp. and Listeria spp. invade nonprofession-
al phagocytes, but then escape from vacuoles into the
cytosol [115]. Infected host cells express recognition
patterns, which trigger a significant immune response. The
specific interaction of host cells to implant-associated
infections caused by Listeria spp. and Salmonella spp. is
unknown. Listeria spp. can persist on stainless steel and
produce biofilm in various amounts. On the other hand,
strains with increased biofilm formation are phylogenically
not associated with those causing invasive diseases [116].
Salmonella spp. can form biofilms on stainless steel, glass,
and gallstones also [117], but is rarely found in orthopedic
implant-associated infections. Therefore, direct contact of
facultative intracellular microorganisms with the foreign
body seems not to be the major pathogenic factor. It can
rather be hypothesized that these microorganisms invade
and replicate within host cells in the periprosthetic tissue.
As a consequence, the immune system deploys mechanisms
to kill the bacteria, and hence, involves infected cells in an
acute inflammation.
Small colony variants Small colony variants (SCVs) of
bacteria are subpopulations with one tenth the size of
normal colonies and therefore called SCVs. They can be
internalized by and survive within a variety of nonprofes-
sional phagocytic cells. SCVs have a decreased toxin
production. Hence, they do not harm the host cell but
persist intracellularly [118]. Various implant-related infec-
tions due to SCVs of S. aureus and E. coli have been
described, including infections associated with pacemakers,
ventriculoperitoneal shunts [119], and prosthetic joints [49,
120]. Similar to other intracellular pathogens, the advan-
tages for the bacteria include protection from antibodies,
complement, and antibiotics that penetrate poorly into
mammalian cells. However, in contrast to the obligate or
facultative intracellular bacteria, intracellular SCVs repli-
cate very slowly or not at all. The immunological host
response to this type of infection is largely unknown.
Neither antigen presentation with a serological response nor
granuloma formation have been observed [118]. During
phagocytosis of bacteria with normal phenotypes, a
disruption of actin polymerization sets off the cytokine
and chemokine alarm system. However, in SCVs, activa-
tion of the host immune system is only weak or absent.
Certain bacterial genes involved in important virulence
properties are inactivated or downregulated in SCVs.
Thereby, infected epithelial cells remain viable without
signs of disruption [121]. This poor stimulation of the
immune system is supported by clinical findings in which
SCV infections persist asymptomatically for many years
[120, 122]. We investigated the pathogens and the
periprosthetic tissue in a prosthetic hip-associated infection
due to S. aureus that relapsed after a 23-month symptom-
free interval [120]. Periprosthetic tissue culture also
revealed SCVs. Examination of the tissue samples by
electron microscopy demonstrated intracellular cocci within
fibroblasts (Fig. 3).
Biocompatibility: how to minimize noxious interactions
Biocompatibility refers to the ability of the biomaterial to
perform its desired function in the body without eliciting
adverse local or systemic effects in the recipient [123].
Biomaterial should generate the most appropriate beneficial
cellular or tissue response in a given situation, and optimize
the clinically relevant function of the treatment. The
phenomenon of biocompatibility is reviewed in detail by
Anderson et al. [6]. During the last decade, surfaces of
prosthetic devices have been modified to improve biocom-
patibility [124–127]. The ideal surface depends on the
required function of the device. Artificial joints and internal
fixation devices should be optimally integrated in bone, a
Fig. 3 Transmission electron micrography of a sample obtained from
a hip joint capsule. Intracellular cocci in a fibroblast from peripros-
thetic biopsy are visible. The cell is surrounded by collagen fibers.
Reproduced from Sendi et al. [120] (©2006, by permission of Oxford
University Press)
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process which is called osteointegration [128]. This can be
achieved with nanostructured titanium. These nanophase
materials enhance osteoblast cell proliferation and thereby
favor osteointegration [124, 125, 129–131]. In addition, the
incorporation of nanoparticles in bone cement has an
antistaphylococcal effect [132].
In intravascular devices, such as vascular grafts or stents,
biocompatibility consists of minimal clotting activation and
minimal bacterial adhesion to the foreign surface. As
mentioned above, rapid neoendothelialization is crucial for
the resistance of the vascular graft to bacterial seeding. This
may be promoted by nanotechnology [133]. By using an
appropriate nanotopography, it could be shown that
endothelial cells cover polymers similar to natural vascular
endothelium [133, 134]. This suggests that the nanotopog-
raphy promotes a phenotypically correct morphology which
potentially provokes minimal local thrombosis or bacterial
adhesion.
On the other hand, hyperneoendothelialization decreases
biocompatibility, also. Small stents used for coronary arteries
are endangered by occlusion due to neointimal hyperplasia
[135]. Therefore, drug-eluting stents releasing an antiproli-
ferative drug (paclitaxel, sirolimus) have been developed
[136, 137]. Drug-eluting stents have been shown to reduce
neointimal hyperplasia, risk of restenosis, and need for
repeated revascularization [138–141]. Theoretically, drug-
eluting stents may have an increased risk for infection due to
the delayed covering by endothelial cells, and thereby,
favoring bacterial adherence. However, coronary stent
infection is extremely rare, and drug-eluting stents have not
been shown to be at increased risk for infection [142–144].
Complement activation on device surfaces is a further
important issue for biocompatibility because of its contri-
bution to the coagulation pathway and local inflammation
(see above “Interaction of implanted device with host
defense mechanisms” section). Therefore, nanotechnology
has also been tested for its influence on complement
activation. It has been shown that complement activation is
more pronounced when blood is in contact with a 200-nm
than with a 20-nm-pore-size membrane [126].
Recently, novel techniques of surface coating have been
shown to prevent unspecific protein adsorption and opti-
mize desired cell adhesion (e.g., fibroblasts) [145]; thereby,
bacterial adherence on the surface is inhibited [146, 147]. A
further promising approach is the use of IL-12. This
cytokine stimulates the Th1 response, and hence, activates
macrophages, which may play a role at the interphase of the
implant. The favorable effect of IL-12 nanoscale coating at
the interface between implant and tissue could be demon-
strated in a rat model. In open fractures treated with
intramedullary bone fixation, the infection rate dropped
from 90% to 20% when an appropriate IL-12 concentration
was used for coating [147].
Conclusions and outlook
Implants are not passive in the host. The foreign surface
interacts with granulocytes, macrophages, and complement
resulting in local inflammation. Due to the increased
susceptibility to infection, even a minimal number of
bacteria (e.g., 100 CFU S. aureus) can colonize the implant.
Device-adhering bacteria transform into a biofilm which
resists phagocytic killing as well as most antimicrobial
agents. In view of these potential problems endangering the
function of the device, strategies protecting implants from
infection are needed.
There are some novel techniques that may minimize
the susceptibility of implants to infection. Coating of
the implant surface with antimicrobial substances such
as antibiotics (minocyclin plus rifampin), antimicrobial
peptides, or silver is an option. This strategy has been
tested in vitro, in experimental models, and partially
also in clinical medicine [148, 149]. An upcoming and
promising technology is the use of “Microsystems
Technology,” also known as Micro-Electro-Mechanical
Systems (MEMS). Ehrlich et al. [148] plan to develop a
self-diagnosing, self-treating, and self-monitoring artifi-
cial joint that resists implant-associated biofilms. The
concept is an implant with a MEMS-type biosensing
device that perceives bacterial communication, also
known as quorum sensing [149]. Quorum sensing is crucial
for biofilm bacteria. It initiates after adherence of micro-
organisms on the surface of an implant. Interference with
this quorum sensing and/or local release of antimicrobial
agents upon sensing of an early biofilm may prevent clinical
infection and loosening of the device.
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